Cobalt are currently contributing to more than 20 research projects
Cobalt has a dedicated Research Group led by Professor Iain Lyburn and a Research Committee whose members include several highly regarded clinicians working within the research fields of dementia and oncology. The committee meets regularly to review the current projects as well as consider any other innovations or new exciting projects which may have been presented to us. Most recently this has resulted in a very important project, (our first ever research project involving ultrasound imaging) which is looking into the treatment of cancer patients that are at high risk of developing venous thromboembolism (blood clots).
Cobalt also has an exciting joint venture with the 2gether NHS Foundation Trust to develop dementia research. In addition to funding specialist scans utilising state-of-the-art equipment for patients with Young Onset Dementia, we are also funding two dementia research nurses to recruit patients into clinical trials. Read more on the 2gether NHS Foundation Trust website.
Gordon Wilcock, DM, FRCP, (Hon) DSc, is Cobalt's Scientific Advisor on dementia, he advises the Board and Research Group on our research dementia strategy. He is an Honorary Consultant Physician at the 2gether NHS Foundation Trust in Gloucestershire, and an Emeritus: a) Professor of Geratology, and b) Consultant in Geriatric Medicine, at Oxford. He has been involved in research into Alzheimer’s disease for over 30 years.
We have also developed a research MRI facility on the campus of the Queen Elizabeth Hospital in Birmingham. This new imaging centre will support the Institute of Translational Medicine with numerous research studies, working with Birmingham Health Partners, a partnership between University Hospitals Birmingham NHS Foundation Trust, the University of Birmingham and Birmingham Children's Hospital NHS Trust.
We are also an important centre for cancer research and are currently contributing PET imaging services for 12 different oncology studies, including several national and international projects covering areas such as Lymphoma, Oesophageal cancer, Myeloma and Lung cancer.
Many of these projects are involved in studying the effects of current treatments for cancer or establishing the efficacy of new and novel cancer drug treatments, all of which have the potential to make effective contributions in providing measurable differences in the management and treatment of these illnesses which could provide real benefits to patients both in the short and long term.
All of our dementia and oncology projects contribute to our over-arching research strategy of further developing our highly regarded, research active, organisation. This encourages interdisciplinary working between researchers and staff both within and beyond Cobalt, across the whole health community, with industry and with potential academic partners, for the benefit of our patients.